key: cord-0743566-2luuw0jh authors: Papadopoulos, Elektra J.; Stein, Kenneth Martin; Voloshko, Polina; Seltzer, Jonathan; Senatore, Fortunato; Browing, Lt Stephen; Faulkner, Ken title: The COVID-19 Pandemic and Cardiovascular Issues in Clinical Trials: Practical and Regulatory Issues in Remote Monitoring of Cardiac Safety date: 2021-09-20 journal: Am Heart J DOI: 10.1016/j.ahj.2021.09.005 sha: 32c2440c0db824a561b6c191716ea09aba8ae341 doc_id: 743566 cord_uid: 2luuw0jh nan setting, these usually require video interaction. Some assessments may not be practical for remote administration, and there may be a risk to patients due to site staff not being nearby in the event of an imminent safety concern (such as a positive suicidality score).  Observer-reported outcomes (ObsROs), based on a report of observable signs, events or behaviors related to a patient's health condition by someone other than the patient or a healthcare professional. Challenges include ensuring intra-observer variability, ability to assess behaviors remotely, and training of non-healthcare personnel. Performance outcomes (PerfOs), based on a standardized task performed by a patient that is administered and evaluated by an appropriately trained individual or is independently completed. Challenges here may include the difficulty of doing some tests remotely (e.g. the 6MWD), safety considerations, the need for special equipment and an appropriate environment, difficulties in observing and recording assessments, and validity compared to measurements taken in the clinic. involve bringing together manufacturers, regulators and clinical thought-leaders; nurturing a collaborative pre-competitive environment; improving knowledge, enhancing innovation and public health; and examining key cardiac safety research issues. The focus of the think tank was to address the challenges and opportunities imposed upon the drug development process as a result of the COVID-19 pandemic. The definition of remote data and methods of aquisition are shown in Table 2 . These mostly include hemodynamics (heart rate and blood pressure), cardiac rhythms, clinical outcome assessment data (e.g., patient-reported outcomes), exercise capacity, and adverse event solicitation. Regulatory considerations for DHT-derived endpoints are broadly similar to the evidentiary considerations for other types of outcome measures. These include the need to confirm that the assessment is valid, reliable and fit for purpose. In collection of these assessments, care must be taken to consider the method of remote communication. A consistent method such as telephone or video should be used: identities of both the patient and healthcare provider should be confirmed: patient privacy must be maintained (both at the patient's location and at the clinic): and clinical trial personnel should be adequately trained on tools and methods. During the pandemic, with the need to acutely switch to another modality to minimize missing data may lead to an increase in data variability. FDA's 'Patient-Focused Drug Development discussion documents 9,10 outline a suggested pathway with upcoming FDA guidance to be issued and further detail on this guidance series can be found on the FDA website. 11 It is also anticipated that CDER will issue two draft guidance documents in 2021, one on the use of digital health technologies for remote data acquisition in clinical investigations and another on decentralized clinical trials. 12 FDA statements on the use of innovative methods of data capture are shown in Table 3 , reflecting their potential to provide suitable information on physical function that can lead to a regulatory action. on some of the issues related to remote monitoring. These include the need to ensure patient safety and privacy, data quality and integrity comparable to that achieved with non-virtual data collection (e.g. missing data should be minimized, and sufficient data must be collected). Clinical training is needed to adapt to changes to procedures and for proper use of virtual tools. Future FDA guidance is expected to address decentralized clinical trials, and the use of digital health technologies for remote data acquisition in clinical investigations. The European Medicines Agency released similar guidance ( Table 4) . During the public health emergency when mid-study changes to remote data collection are made,it is important to document whether an assessment was conducted in-person or remotely (including type of technology used), and it may also be necessary to make adaptations to the study power and statistical analysis. Some adaptations may include including methods for handling missing data, the potential need to compare data acquired via different modalities, any impact on compliance, and ways to account for additional variability that might affect study power or require additional patients to be enrolled. To be considered as supporting data for a regulatory approval, remote data would need to meet the evidentiary standard for a substantive review. This is not unique to or exacberated by COVID. First, the acquired data should be poolable. Actigraphy passively measures patients' daily activity. It is not equivalent to a 6MWD which, in contrast, is a structured task-based assessment administered according to a set of instructions. Substituting actigraphy for 6MWD in a protocol amendment as a pandemic precaution creates the potential for pooling two non-combinable outcomes. Second, management strategies would need to be capable of distinguishing a clinically meaningful treatment effect. This involves well-defined variability with the selected DHTT. For claims related to clinical benefit using a clinical outcome assessment, it is important to demonstrate that the endpoint score is clinically meaningful, and to assess how much within-patient change in score or variable is meaningful. Feasibility and usability are critical considerations. Finally, operational challenges may threaten pivotal trial adequacy such as subjects' possession of requisite equipment, adequate knowledge of the equipment's use, and protocol compliance (such as avoiding taking off a watch or ambulatory blood pressure monitoring device). As the clinical trials community incorporates increasing numbers of remote visits into protocols, the questions below will need to be considered:  How does one ascertain whether clinical measurements are candidates for remote collection?  What are the basic requirements for remote monitoring DHTs to be considered for use in clinical trials?  How are specific DHTs classified based on their function?  What are reasonable components for study endpoints?  What functionalities are available?  How should a remote/mobile DHT be selected for a particular use?  How much customization is required to tailor the DHT for a specific protocol design?  Can remote DHTs adequately evaluate both safety and efficacy?  Can patient privacy be maintained in a remote setting, both at the patient's location and at the clinic?  What are the regulatory implications of moving assessments to a remote modality?  What are the regulatory requirements in terms of validation of these devices? The COVID-19 pandemic has heralded a new era in clinical trials via the digital health platform, remote data acquisition, and remote data monitoring. From a regulatory perspective, remote data capture is a viable strategy for pivotal trials with endpoints measured outside of traditional office or clinic visits, in areas including exercise capacity and patient reported outcomes. Clinical outcome assessments must also be carefully evaluated for use in drawing conclusions about safety and efficacy, and to derived clinical trial endpoints to support labeling claims. The variability of measures should be estimated and the results should produce a clinically meaningful treatment effect. Challenges impacting the quality of evidence include undefined variability, protocol amendments resulting in measurement of noncombinable outcomes, and operational threats to assessment of trial adequacy. Timely FDA guidance has helped those on the front lines of clinical trials to make decisions about data collection modes, what data to exclude, and where recruitment may need to be expanded. Looking ahead, more clarity is needed in defining best practices for remote data gathering, and for appropriate use of a combination of remote and traditional approaches to inform post-COVID-19 approaches. Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency: Guidance for Industry, Investigators, and Institutional Review Boards New precompetitive paradigms: focus on cardiac safety The Cardiac Safety Research Consortium enters its second decade: An invitation to participate Cancer researchers claim 'extraordinary results' using T-cell therapy. The Guardian Regulatory Perspective: Digital Health Technology Tools: Use in Clinical Investigations to Evaluate Clinical Benefit in Patients. DIA Global Forum From the immune contexture to the Immunoscore: The role of prognostic and predictive immune markers in cancer Heart rhythm bodies see 'clear concerns' with using wearables to detect arrhythmias Pharmacogenetics of drug hypersensitivity (Table 1) FDA's Comprehensive Effort to Advance New Innovations: Initiatives to Modernize for Innovation. FDA Voices The authors thank Jill Dawson, Ph.D., for medical writing support.